(Denver, Colo—9 a.m. Eastern, October 5, 2022) – Expanding the eligibility criteria for low-dose CT screening for lung cancer can increase the number of women and Black persons who can benefit from screening, according to a study published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.
LDCT screening reduces lung cancer mortality, but current eligibility guidelines hamper its use.
“LDCT is underutilized by the currently eligible population, with estimated state-level participation rates ranging from 1% to 14%,” said Raymond Uyiosa Osarogiagbon, MBBS, FACP Baptist Cancer Center Memphis, Tennessee. The current screening criteria are imperfect- even with 100% adoption, only 20% to 40% of the US lung cancer population would be eligible to participate. Additionally, LDCT screening guidelines exacerbate existing racial and sex-based disparities because women and racial minorities develop lung cancer at a younger age and with less intense cigarette tobacco exposure than White men, upon whose risk the eligibility criteria are mostly based.
For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
Osarogiagbon and colleagues sought to validate their theory that expanding eligibility guidelines for LDCT screening would benefit women and Black persons.
From 2015 on, Osarogiagbon and his research team implemented a guideline-concordant Incidental Lung Nodule Program at the Baptist Memorial Hospital in Memphis, Tennessee. In 2019, they started disseminating this program across BMHCC institutions in Arkansas, Mississippi and Tennessee, to reach a service area population across 111 counties in this region. The population in these counties has some of the highest US per-capita lung cancer incidence and mortality rates and a high proportion of Black persons.
Using data from the Lung Nodule Program, his research group compared persons eligible for LDCT by five different screening protocols:
US Preventive Services Task Force (USPSTF) 2013 criteria (55-80 years, ≥30 pack-years of smoking, and ≤15 years since cessation (USPSTF2013);
2) USPSTF 2021 (50-80 years, ≥20 pack-years of smoking, and ≤15 years since cessation (USPSTF2021);
3) quit duration expanded to ≤25 years (USPSTF2021-QD25);
4) reducing the pack-years of smoking to ≥10 (USPSTF2021- PY10);
5) and both (USPSTF2021-QD25-PY10)
Of the 17,421 individuals analyzed, 56% were female, 69% were White, and 28% were Black. Of these study participants 13% met USPSTF2013 criteria; 17% USPSTF2021; 18% USPSTF2021-QD25; 19% USPSTF2021-PY10; 21% USPSTF2021-QD25-PY10.